Physician profile
Michael Gabriel
NPI 1801894902
$2,883.14
in general payments reported to CMS, 2019-2025
25 companies · $367 in 2025
The $367 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $52.56 · 2021: $171 · 2022: $375 · 2023: $605 · 2024: $739 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $343.35 | 2019-2025 | Bexsero |
| Sanofi Pasteur INC. | $295.84 | 2019-2025 | |
| Phadia US INC. | $290.45 | 2019-2024 | Immunocap |
| Janssen Pharmaceuticals, INC | $247.52 | 2019 | |
| Pfizer INC. | $225.51 | 2019-2025 | |
| Corium, LLC | $214.94 | 2023-2025 | Azstarys |
| Kaleo, INC. | $165.79 | 2021-2024 | Auvi-Q |
| Sobi, INC | $139.82 | 2019-2023 | |
| Seqirus USA INC | $137.14 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Sanofi-Aventis U.S. LLC | $110.34 | 2024-2025 | |
| Cumberland Pharmaceuticals, INC. | $107.66 | 2022-2023 | Kristalose |
| Cranial Technologies, INC | $106.11 | 2021-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $102.81 | 2022-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Biomarin Pharmaceutical INC. | $61.84 | 2024 | Voxzogo 1.2mg |
| Cognoa, INC. | $53.48 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $43.27 | 2024 | Ycanth |
| Ars Pharmaceuticals Operations, INC. | $34.18 | 2025 | Neffy |
| Genentech USA, INC. | $33.02 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $31.52 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $30.27 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $28.68 | 2024 | Flumist Quadrivalent |
| Neurelis, INC. | $23.88 | 2024 | Valtoco |
| Alexion Pharmaceuticals, INC. | $21.71 | 2025 | Koselugo |
| Alk-Abello, INC | $19.78 | 2023 | Grastek, Odactra, Ragwitek |
| Ortho-Clinical Diagnostics, INC. | $14.23 | 2024 | Sofia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gabriel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.